An international team led by Australia’s Walter and Eliza Hall Institute (WEHI) has created the first authoritative atlas for a class of enzymes that regulate almost every cellular process in the human body. The new atlas identifies 672 high-confidence E3 ligases and provides a new reference framework for disease biology and targeted protein degradation research. Read More
CDR-Life Inc. has announced the achievement of the first preclinical milestone under its 2025 license agreement with Boehringer Ingelheim Pharma GmbH & Co. KG. This milestone underscores progress in the companies’ efforts to develop next-generation antibody-based therapies for autoimmune diseases. Read More
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has announced IND approval by China’s National Medical Products Administration (NMPA) for SKB-103 for the treatment of advanced solid tumors. Read More
Immutrin Ltd. has successfully raised £65 million ($87 million) in series A financing to advance its lead asset through clinical proof of concept in ATTR cardiomyopathy. Immutrin’s novel antibody selectively binds to amyloid fibrils and is engineered to deplete amyloid deposits in tissue via a targeted and coordinated immune response. Read More
Glyconex Inc. has entered into a collaboration agreement with Nippon Kayaku Co. Ltd. to advance GNX201-ADC, a next-generation glycan-directed antibody-drug conjugate (ADC) candidate for the treatment of solid tumors. Read More
Insitro Inc. has expanded its strategic collaboration with Bristol Myers Squibb Co. to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS). Read More
Soluble amyloid-β oligomers (AβOs) are known early drivers of Alzheimer’s disease pathogenesis. Acumen Pharmaceuticals Inc. has recently presented data generated in the development and characterization of anti-AβO antibodies with high selectivity for AβO over Aβ monomers. Read More
Apex Biosciences Pte. Ltd. has identified phosphodiesterase (PDE) inhibitors reported to be useful for the treatment of arthritis, coronary artery diseases, idiopathic pulmonary fibrosis, inflammatory bowel disease, metabolic dysfunction-associated steatohepatitis, neurodegeneration, obstructive sleep apnea and cancer. Read More
Endomet Biosciences Inc. (dba Endocyclic Therapeutics) has obtained IND clearance from the FDA for its lead program, ENDO-205, a first-in-class, nonhormonal targeted peptide therapeutic for endometriosis. Read More
Overt Bio Inc. is advancing lead asset OVT-101 toward the clinic. The allogeneic, potential first-in-class, off-the-shelf γδ CAR T therapy targets claudin-6, which is present in the majority of ovarian cancers and several other solid tumors. Read More
Scientists from Nanyang Biologics Pte. Ltd. and Nanyang Technological University have divulged molephantinin derivatives reported to be useful for the treatment of colorectal cancer. Read More
The Council of Scientific and Industrial Research has disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer. Read More
Simcere Zaiming Pharmaceutical Co. Ltd. has synthesized coumarin compounds targeting mitogen-activated protein kinase kinase reported to be useful for the treatment of cancer. Read More
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has prepared and tested molecular glue degraders comprising E3 ubiquitin-protein ligases acting as proto-oncogene Vav (VAV1) degradation inducers reported to be useful for the treatment of inflammation and autoimmune diseases. Read More
A team at the Virginia Polytechnic Institute and State University applied a drug repurposing strategy and screened a library of 2,528 small molecules targeting G protein-coupled receptors (GPCRs) and related signaling pathways for the ability to inhibit the growth of Neisseria gonorrhoeae. Read More
